Is tirzepatide legal in the United States?

Tirzepatide is FDA-approved and prescription only, and this guide explains the compounding limits and FDA warning letters to research-labeled sellers, as of November 17, 2026.

Basics6 min read

Key takeaway

Tirzepatide is FDA-approved as Mounjaro (May 13, 2022) and Zepbound (November 8, 2023), both from Eli Lilly and both prescription only. FDA declared the tirzepatide injection shortage resolved on December 19, 2024, and its temporary compounding allowances ended in March 2025. FDA has sent warning letters to sellers of research-labeled tirzepatide, most recently in August 2026. Tirzepatide is not on the DEA’s controlled substances list.

At a glance

Article typeBasics
Main guideTirzepatide: complete guide
Regulatory statusFDA-approved“Tirzepatide is the first FDA-approved dual agonist” (Tirzepatide: complete guide)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited0 in this article · 10 across 15 articles on Tirzepatide
ProductTirzepatide product page

Is tirzepatide legal in the United States? Yes, as a prescription medicine. FDA has approved it twice, as Mounjaro and Zepbound. The harder questions are about compounding after the shortage ended, and about tirzepatide sold outside the prescription system. This guide takes them one at a time, using Drugs@FDA, DailyMed, FDA orders and warning letters checked on November 17, 2026.

Quick answer: Tirzepatide is legal to prescribe and dispense as Mounjaro or Zepbound. Compounding is now limited. A 503A pharmacy may not regularly compound copies of the approved products, and a 503B outsourcing facility does not meet the 503B conditions when it compounds tirzepatide from bulk. FDA treats tirzepatide sold for human use outside an approved application as an unapproved new drug, and a “research use only” label has not changed that when marketing showed human use. Research-grade tirzepatide is a laboratory reagent, not an alternative to a prescription medicine.

This article summarizes public regulatory records. It is not legal advice. For a decision about your own situation, ask a lawyer.

Is tirzepatide FDA-approved?

Yes. Drugs@FDA lists two applications from Eli Lilly, both with marketing status “Prescription”:

  • Mounjaro, NDA 215866, approved May 13, 2022 as a new molecular entity (Drugs@FDA); and
  • Zepbound, NDA 217806, approved November 8, 2023 (Drugs@FDA).

The current Mounjaro label, revised in August 2026, lists two uses: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk of them (DailyMed). The current Zepbound label, also revised in August 2026, lists use with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction in adults with obesity, or adults with overweight and at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity (DailyMed). For what the approved labels contain, see our page on semaglutide and tirzepatide prescription labels. For costs, see tirzepatide price.

Can tirzepatide still be compounded?

Only within narrow limits. Tirzepatide injection products were added to FDA’s shortage list on December 15, 2022. In a declaratory order dated December 19, 2024, FDA determined “that the tirzepatide injection product shortage is resolved” (FDA, 2024). FDA then gave compounders a wind-down period. After a court denied a preliminary injunction on March 5, 2025, FDA said the 503A period had ended; the 503B period ran to March 19, 2025 (FDA, 2026). On August 27, 2026, the Fifth Circuit affirmed judgment for FDA in the compounders’ challenge (No. 25-10600).

FDA’s current policy, updated April 1, 2026, sets out what remains:

  • 503A pharmacies must compound for an individual patient on a prescription and may not compound essentially copies of a commercially available product “regularly or in inordinate amounts.” FDA does not intend to act against a pharmacy that fills four or fewer prescriptions of such a copy in a calendar month.
  • 503B outsourcing facilities may compound from a bulk substance only if it is on the 503B bulks list or the drug is on the shortage list. FDA wrote: “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.”

On April 30, 2026, FDA proposed not to include tirzepatide on the 503B bulks list, finding “no clinical need” (FDA, 2026). Comments closed on July 30, 2026, and we found no final decision. In an April 7, 2026 warning letter, FDA told a registered outsourcing facility that its tirzepatide products were not eligible for the 503B exemptions because “tirzepatide does not appear on the 503B bulks list” (FDA, 2026). Compounded drugs are not FDA-approved. Our pages on compounded tirzepatide and 503A vs 503B compounding cover the details.

Has FDA warned sellers of unapproved tirzepatide?

Yes. FDA says it has warned companies that sold unapproved semaglutide, tirzepatide and similar products “falsely labeled” for research purposes or not for human consumption (FDA, 2026). Table 1 shows the letters and status checks we read.

Table 1

Tirzepatide: approvals, FDA actions and status checks

Date What happened
May 13, 2022 FDA approves Mounjaro (NDA 215866)
November 8, 2023 FDA approves Zepbound (NDA 217806)
September 12, 2024 Warning letter to an online seller of tirzepatide and semaglutide sold without a prescription
December 10, 2024 Warning letter to a seller of tirzepatide labeled “research use only”
December 19, 2024 FDA order: tirzepatide injection shortage resolved
February 26, 2025 Warning letter over tirzepatide labeled “research use only” and “not for human consumption”
March 19, 2025 Last day of FDA’s 503B wind-down period
February 20, 2026 Warning letter over compounded tirzepatide marketed as having the same active ingredient as Mounjaro and Zepbound
March 31, 2026 Warning letter to a seller of research-labeled tirzepatide and retatrutide
April 30, 2026 FDA proposes not to include tirzepatide on the 503B bulks list
August 24, 2026 Warning letters to two sellers of research-labeled tirzepatide
November 12, 2026 DEA controlled substances list edition; tirzepatide not listed

The research-labeled cases follow one pattern. The February 2025 letter named a product listed as “Tirzepatide (Mounjaro)” and quoted “research use only” and “not for human consumption.” The March 2026 letter quoted “Research Use Only.” The August 2026 letter to Tex Peptides quoted “not for human or veterinary use.” Each time, FDA wrote that evidence from the seller’s website established that the products were intended to be drugs for human use, and cited sections 505(a) and 301(d) of the Act. Our guide to FDA warning letters to peptide sellers lists each letter.

Is tirzepatide a controlled substance?

Not under federal law. Tirzepatide does not appear on the DEA’s alphabetical list of controlled substances, edition dated November 12, 2026 (DEA). That does not make a product lawful to sell as a drug. That question belongs to FDA.

What does research-use-only sale mean, and what are its limits?

A “research use only” label states the seller’s intended use: laboratory research, not use in people or animals. Research-grade tirzepatide is a laboratory reagent. It is not Mounjaro or Zepbound, it is not made under an approved application, and it is not a substitute for a prescription medicine.

The label does not decide the legal question by itself. FDA judges intended use by “objective intent,” which may be shown by a seller’s expressions or “the circumstances surrounding the distribution of the article” (21 CFR 201.128). When the evidence shows a product is meant for people, FDA can treat it as an unapproved new drug despite the label, as the letters above show.

Research-grade tirzepatide in our catalog is sold for laboratory research use only, not for human or veterinary use. See also what research use only means.

Frequently asked questions about tirzepatide legality

Is tirzepatide FDA-approved?

Yes, as Mounjaro (2022) and Zepbound (2023). Both are prescription-only.

Can a pharmacy still compound tirzepatide?

Only within limits. A 503A pharmacy may not regularly compound copies of the approved products. Tirzepatide is on neither the 503B bulks list nor FDA’s shortage list.

Does a “research use only” label make tirzepatide legal to sell?

Not by itself. FDA decides intended use from all the evidence. When that evidence showed human use, FDA treated research-labeled tirzepatide as an unapproved new drug.

Is tirzepatide a controlled substance?

No. It is not on the DEA’s federal list.

Is research-grade tirzepatide the same as Mounjaro or Zepbound?

No. The approved products are made and labeled under an FDA-approved application. Research-grade material is for laboratory research use only and is not an alternative to them.

What to know now

  • FDA approval: Mounjaro (2022) and Zepbound (2023), prescription only.
  • Shortage: resolved December 19, 2024; wind-down periods ended in March 2025.
  • 503B: not on the bulks list or the shortage list; FDA proposed leaving it off the list.
  • Enforcement: warning letters from 2024 to August 2026 looked past research-use labels.
  • Controlled substance: not on the DEA’s federal list.
  • Research grade: for laboratory research use only, not for human or veterinary use.

What we’re watching

FDA’s final decision on its proposal to leave tirzepatide off the 503B bulks list. New FDA warning letters to sellers of research-labeled tirzepatide. And further label changes for Mounjaro and Zepbound listed on Drugs@FDA.

Also in the library

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: U.S. Food and Drug Administration. Drugs@FDA: Mounjaro (tirzepatide), Drugs@FDA: Mounjaro (tirzepatide), NDA 215866; U.S. Food and Drug Administration. Drugs@FDA: Zepbound (tirzepatide), Drugs@FDA: Zepbound (tirzepatide), NDA 217806; Eli Lilly and Company 2026, Mounjaro (tirzepatide) injection: Prescribing information; Eli Lilly and Company 2026, Zepbound (tirzepatide) injection: Prescribing information; U.S. Food and Drug Administration 2024; U.S. Food and Drug Administration 2026, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize; United States Court of Appeals for the Fifth Circuit 2026, Outsourcing Facilities Association v. Food & Drug Administration; U.S. Food and Drug Administration 2026, FDA proposes to exclude semaglutide, tirzepatide and liraglutide on 503B bulks list; Food and Drug Administration 2026, Federal Register, 91; U.S. Food and Drug Administration 2026, Warning letter: ProRx LLC, MARCS-CMS 723704; U.S. Food and Drug Administration 2026, FDA’s concerns with unapproved GLP-1 drugs used for weight loss; U.S. Food and Drug Administration 2024, Warning letter: Nomida.biz, MARCS-CMS 687590; U.S. Food and Drug Administration 2024, Warning letter: Summit Research Peptides, MARCS-CMS 695607; U.S. Food and Drug Administration 2025, Warning letter: USApeptide.com, MARCS-CMS 696885; U.S. Food and Drug Administration 2026, Warning letter: MEDVi, LLC dba MEDVi, MARCS-CMS 721455; U.S. Food and Drug Administration 2026, Warning letter: Gram Peptides, MARCS-CMS 721806; U.S. Food and Drug Administration 2026, Warning letter: Peptide Partners LLC, MARCS-CMS 735063; U.S. Food and Drug Administration 2026, Warning letter: TXP Innovations LLC dba Tex Peptides, MARCS-CMS 735067; U.S. Drug Enforcement Administration 2026, Controlled substances: Alphabetical order; Code of Federal Regulations. 21 CFR 201.128: Meaning of “intended uses” . Legal Information Institute, 21 CFR 201.128: Meaning of “intended uses”. All 20 citations

Back to the research library

References

  1. U.S. Food and Drug Administration. Drugs@FDA: Mounjaro (tirzepatide), NDA 215866. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866
  2. U.S. Food and Drug Administration. Drugs@FDA: Zepbound (tirzepatide), NDA 217806. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806
  3. Eli Lilly and Company. (2026). Mounjaro (tirzepatide) injection: Prescribing information (revised August 2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  4. Eli Lilly and Company. (2026). Zepbound (tirzepatide) injection: Prescribing information (revised August 2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  5. U.S. Food and Drug Administration. (2024, December 19). Declaratory order: Resolution of shortages of tirzepatide injection products (Mounjaro and Zepbound). https://www.fda.gov/media/184606/download
  6. U.S. Food and Drug Administration. (2026). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current as of April 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  7. United States Court of Appeals for the Fifth Circuit. (2026, August 27). Outsourcing Facilities Association v. Food & Drug Administration, No. 25-10600. https://www.ca5.uscourts.gov/opinions/unpub/25/25-10600.0.pdf
  8. U.S. Food and Drug Administration. (2026, April 30). FDA proposes to exclude semaglutide, tirzepatide and liraglutide on 503B bulks list. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  9. Food and Drug Administration. (2026, June 26). List of bulk drug substances for which there is a clinical need under section 503B of the Federal Food, Drug, and Cosmetic Act; extension of comment period. Federal Register, 91, 38719. https://www.govinfo.gov/content/pkg/FR-2026-06-26/html/2026-12937.htm
  10. U.S. Food and Drug Administration. (2026, April 7). Warning letter: ProRx LLC, MARCS-CMS 723704. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prorx-llc-723704-04072026
  11. U.S. Food and Drug Administration. (2026). FDA’s concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026). https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  12. U.S. Food and Drug Administration. (2024, September 12). Warning letter: Nomida.biz, MARCS-CMS 687590. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nomidabiz-687590-09122024
  13. U.S. Food and Drug Administration. (2024, December 10). Warning letter: Summit Research Peptides, MARCS-CMS 695607. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/summit-research-peptides-695607-12102024
  14. U.S. Food and Drug Administration. (2025, February 26). Warning letter: USApeptide.com, MARCS-CMS 696885. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/usapeptidecom-696885-02262025
  15. U.S. Food and Drug Administration. (2026, February 20). Warning letter: MEDVi, LLC dba MEDVi, MARCS-CMS 721455. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medvi-llc-dba-medvi-721455-02202026
  16. U.S. Food and Drug Administration. (2026, March 31). Warning letter: Gram Peptides, MARCS-CMS 721806. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
  17. U.S. Food and Drug Administration. (2026, August 24). Warning letter: Peptide Partners LLC, MARCS-CMS 735063. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026
  18. U.S. Food and Drug Administration. (2026, August 24). Warning letter: TXP Innovations LLC dba Tex Peptides, MARCS-CMS 735067. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/txp-innovations-llc-dba-tex-peptides-735067-08242026
  19. U.S. Drug Enforcement Administration, Diversion Control Division. (2026, November 12). Controlled substances: Alphabetical order. https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf
  20. Code of Federal Regulations. 21 CFR 201.128: Meaning of “intended uses”. Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/cfr/text/21/201.128